Managing the challenges of pharmaceutical patent expiry: a case study of Lipitor

Author:

Chao Chon Kit,Hu Hao,Zhang Liming,Wu Jihong

Abstract

Purpose The paper aims to study how global pharmaceutical companies such as Pfizer have managed the challenges of pharmaceutical patent expiry. Design/methodology/approach A case study method was applied. The best-selling brand drug over the past 10 years – Lipitor – was chosen as the case target. Findings For dealing with this, this paper describes all the details of the corresponding strategies of Pfizer before and after patent expiration of Lipitor. Before patent expiry, Pfizer undertook the activities of direct-to-consumer marketing, pricing strategy for competition, legal delay and me-too drug R&D. After patent expiry, Pfizer chose to carry out continuous marketing for brand, rebate strategy, authorized generics and change to over-the-counter. In addition, diversity and globalization strategy was applied before and after patent expiry. Research limitations/implications This research provides strong implication for managing pharmaceutical products before and after patent expiry. Practical implications It is strongly recommended for both brand and generic drug companies to design strategies to meet the challenges of pharmaceutical patent expiry. Social implications For the global pharmaceutical market, a conclusion can be drawn that, nowadays, the “patent cliff” is the most significant factor influencing decision-makers to consider futuristic policies. Further, it is also a considerably effective solution for reducing health-care costs for policymakers. Originality/value This paper contributes to the field of patent expiry management in high-tech industries such as pharmaceuticals.

Publisher

Emerald

Reference53 articles.

1. Prescription drug spending trends in the US: looking beyond the turning point;Health Affairs,2009

2. Authorized generic entry prior to patent expiry: reassessing incentives for independent generic entry;Review of Economics and Statistics,2015

3. Pricing policies to handle patent loss or expiry;Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing,2003

4. Beasley, D. (2011), “Branded drug prices soar as generic pressure rises”, available at: www.reuters.com/article/2011/03/23/us-branded-drug-prices-idUSTRE72M57X20110323 (accessed 23 March 2011).

5. Pharmaceuticals in US health care: determinants of quantity and price;Journal of Economic Perspectives,2002

Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3